SCHEMBL5451654

SCHEMBL5451654

NC(=O)c1c(NC(=O)Nc2ccc(-c3ccccc3)cc2)sc2c1CCSC2

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 1/20 0.54
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
EPHB4 P54760 1/20 0.51
KCNH2 Q12809 10/20 0.50
ALDH1A1 P00352 2/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 1/20 0.50
PTPN1 P18031 1/20 0.48
PTPRA P18433 1/20 0.48
FLT3 P36888 2/20 0.47
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
TLR2 O60603 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451378 0.89 TNIK (0.52) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5447105 0.87 KMT2A (0.58) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5455850 0.87 FLT3 (0.53) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5452256 0.87 TLR2 (0.53) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5448370 0.85 MEN1 (0.68) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5457467 0.85 FLT3 (0.56) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5467129 0.84 TNIK (0.50) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5454155 0.84 KCNH2 (0.49) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5451319 0.84 KCNH2 (0.52) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5453159 0.84 FLT3 (0.55) TNIKNPC1RAB9AKCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 TNIK 4134/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.